Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 57
Filter
1.
Clin Lymphoma Myeloma Leuk ; 23(5): e232-e239, 2023 05.
Article in English | MEDLINE | ID: mdl-36863897

ABSTRACT

Introduction We report the results of a phase I clinical trial NCT03790072 of an adoptive transfer of γδ T lymphocytes from haploidentical donors in patients with refractory/relapsed acute myeloid leukemia after lymphodepletion regimen. Patients and methods Healthy donor mononuclear cells collected by leukapheresis were consistently expanded to generate products of 109 to 1010 γδ T cells. Seven patients received donor-derived T cell product at doses of 106/kg (n = 3), 107/kg (n = 3), and 108/kg (n = 1). Results Four patients had bone marrow evaluation at day 28. One patient had a complete remission, one was classified as morphologic leukemia-free state, one had stable disease and one had no evidence of response. In one patient, there was evidence of disease control with repeat infusions up to 100 days after first dosing. There were no treatment-related serious adverse events or treatment-related Common Terminology Criteria for Adverse Events grade 3 or greater toxicities at any dose level. Allogeneic Vγ9Vδ2 T cell infusion was shown to be safe and feasible up to a cell dose of 108/kg. Discussion In agreement with previously published studies, the infusion of allogeneic Vγ9Vδ2 cells was safe. The contribution of lymphodepleting chemotherapy to responses seen cannot be ruled out. Main limitation of the study is the low number of patients and interruption due to COVID-19 pandemic. Conclusion These positive Phase 1 results support progression to phase II clinical trials.


Subject(s)
COVID-19 , Hematopoietic Stem Cell Transplantation , Leukemia, Myeloid, Acute , Humans , Pandemics , Treatment Outcome , Leukemia, Myeloid, Acute/therapy , T-Lymphocytes , Hematopoietic Stem Cell Transplantation/methods
2.
Ann Neurol ; 91(2): 217-224, 2022 02.
Article in English | MEDLINE | ID: mdl-34961965

ABSTRACT

OBJECTIVE: Blindsight is a disorder where brain injury causes loss of conscious but not unconscious visual perception. Prior studies have produced conflicting results regarding the neuroanatomical pathways involved in this unconscious perception. METHODS: We performed a systematic literature search to identify lesion locations causing visual field loss in patients with blindsight (n = 34) and patients without blindsight (n = 35). Resting state functional connectivity between each lesion location and all other brain voxels was computed using a large connectome database (n = 1,000). Connections significantly associated with blindsight (vs no blindsight) were identified. RESULTS: Functional connectivity between lesion locations and the ipsilesional medial pulvinar was significantly associated with blindsight (family wise error p = 0.029). No significant connectivity differences were found to other brain regions previously implicated in blindsight. This finding was independent of methods (eg, flipping lesions to the left or right) and stimulus type (moving vs static). INTERPRETATION: Connectivity to the ipsilesional medial pulvinar best differentiates lesion locations associated with blindsight versus those without blindsight. Our results align with recent data from animal models and provide insight into the neuroanatomical substrate of unconscious visual abilities in patients. ANN NEUROL 2022;91:217-224.


Subject(s)
Nerve Net/physiopathology , Unconsciousness/psychology , Visual Perception , Adult , Aged , Brain Mapping , Connectome , Female , Functional Laterality/physiology , Humans , Male , Middle Aged , Nerve Net/diagnostic imaging , Pulvinar/diagnostic imaging , Pulvinar/physiopathology , Rest , Vision Disorders , Visual Fields , Young Adult
3.
DNA Repair (Amst) ; 84: 102641, 2019 12.
Article in English | MEDLINE | ID: mdl-31311768

ABSTRACT

Ribonucleotides are the most common non-canonical nucleotides incorporated into DNA during replication, and their processing leads to mutations and genome instability. Yeast mutation reporter systems demonstrate that 2-5 base pair deletions (Δ2-5bp) in repetitive DNA are a signature of unrepaired ribonucleotides, and that these events are initiated by topoisomerase 1 (Top1) cleavage. However, a detailed understanding of the frequency and locations of ribonucleotide-dependent mutational events across the genome has been lacking. Here we present the results of genome-wide mutational analysis of yeast strains deficient in Ribonucleotide Excision Repair (RER). We identified mutations that accumulated over thousands of generations in strains expressing either wild-type or variant replicase alleles (M644G Pol ε, L612M Pol δ, L868M Pol α) that confer increased ribonucleotide incorporation into DNA. Using a custom-designed mutation-calling pipeline called muver (for mutationes verificatae), we observe a number of surprising mutagenic features. This includes a 24-fold preferential elevation of AG and AC relative to AT dinucleotide deletions in the absence of RER, suggesting specificity for Top1-initiated deletion mutagenesis. Moreover, deletion rates in di- and trinucleotide repeat tracts increase exponentially with tract length. Consistent with biochemical and reporter gene mutational analysis, these deletions are no longer observed upon deletion of TOP1. Taken together, results from these analyses demonstrate the global impact of genomic ribonucleotide processing by Top1 on genome integrity.


Subject(s)
DNA Repair , DNA Topoisomerases, Type I/metabolism , Mutation Rate , Ribonucleotides/genetics , Saccharomyces cerevisiae Proteins/metabolism , DNA Topoisomerases, Type I/genetics , DNA-Directed DNA Polymerase/metabolism , Dinucleotide Repeats , Gene Deletion , Genomic Instability , Saccharomyces cerevisiae , Saccharomyces cerevisiae Proteins/genetics , Trinucleotide Repeats
4.
BMC Health Serv Res ; 18(1): 346, 2018 05 10.
Article in English | MEDLINE | ID: mdl-29743064

ABSTRACT

BACKGROUND: Self-administration of medicines by patients whilst in hospital is being increasingly promoted despite little evidence to show the risks and benefits. Pain control after total knee replacement (TKR) is known to be poor. The aim of the study was to determine if patients operated on with a TKR who self-medicate their oral analgesics in the immediate post-operative period have better pain control than those who receive their pain control by nurse-led drug rounds (Treatment as Usual (TAU)). METHODS: A prospective, parallel design, open-label, randomised controlled trial comparing pain control in patient-directed self-management of pain (PaDSMaP) with nurse control of oral analgesia (TAU) after a TKR. Between July 2011 and March 2013, 144 self-medicating adults were recruited at a secondary care teaching hospital in the UK. TAU patients (n = 71) were given medications by a nurse after their TKR. PaDSMaP patients (n = 73) took oral medications for analgesia and co-morbidities after two 20 min training sessions reinforced with four booklets. Primary outcome was pain (100 mm visual analogue scale (VAS)) at 3 days following TKR surgery or at discharge (whichever came soonest). Seven patients did not undergo surgery for reasons unrelated to the study and were excluded from the intention-to-treat (ITT) analysis. RESULTS: ITT analysis did not detect any significant differences between the two groups' pain scores. A per protocol (but underpowered) analysis of the 60% of patients able to self-medicate found reduced pain compared to the TAU group at day 3/discharge, (VAS -9.9 mm, 95% CI -18.7, - 1.1). One patient in the self-medicating group over-medicated but suffered no harm. CONCLUSION: Self-medicating patients did not have better (lower) pain scores compared to the nurse-managed patients following TKR. This cohort of patients were elderly with multiple co-morbidities and may not be the ideal target group for self-medication. TRIAL REGISTRATION: ISRCTN10868989 . Registered 22 March 2012, retrospectively registered.


Subject(s)
Arthroplasty, Replacement, Knee/adverse effects , Pain, Postoperative/prevention & control , Administration, Oral , Aged , Analgesia, Patient-Controlled/methods , Analgesia, Patient-Controlled/nursing , Analgesics/administration & dosage , Female , Hospitalization , Hospitals, Teaching , Humans , Male , Pain Management/methods , Pain Management/nursing , Pain Measurement/nursing , Pain, Postoperative/nursing , Prospective Studies , Self Administration , Self-Management/methods , Treatment Outcome
5.
Am J Rhinol Allergy ; 30(2): e30-5, 2016.
Article in English | MEDLINE | ID: mdl-26980383

ABSTRACT

BACKGROUND: Given the differences in pathophysiology between allergic fungal rhinosinusitis (AFRS) and other chronic rhinosinusitis (CRS) subgroups, it remains unclear about whether these patients respond differently to a combination of surgical and medical treatments. OBJECTIVE: To evaluate differences in quality-of-life (QoL) outcomes for a cohort of patients who underwent endoscopic sinus surgery (ESS) for CRS. METHODS: This retrospective review included patients with CRS who underwent ESS between 2010 and 2013. QoL was measured by using the 22-item Sino-Nasal Outcome Test (SNOT-22). Variables collected included baseline demographics, SNOT-22 scores before ESS and at 1, 3, 6, 9, and 12 months after ESS. Groups tested were CRS with nasal polyposis, CRS without nasal polyposis (CRSsNP), and patients with AFRS. A linear mixed- effects regression model was used to calculate the adjusted mean QoL differences. RESULTS: Among the 250 patients included, 61.6% had CRS with nasal polyposis (n = 154), 28.8% had CRSsNP (n = 72), and 9.6% had AFRS (n = 24). Significant differences were seen in SNOT-22 scores between pre- and postoperative visits and between the etiologic subgroups (p < 0.001). Multivariate analysis revealed significantly greater improvement in QoL for patients with AFRS in comparison with those with CRSsNP at the 9-month follow-up (change in SNOT-22 score, 22.6 [95% confidence interval, 1.2-44.1]; p < 0.0) and the 12-month follow-up (change in SNOT-22 score, 20.2 [95% confidence interval, 0.5-39.9]; p < 0.04). CONCLUSIONS: Patients with AFRS experienced a more-prolonged QoL benefit from surgical and targeted medical intervention compared with those with CRSsNP, which may reflect the severity of inflammation that they presented with compared with other CRS subtypes.


Subject(s)
Endoscopy , Fungi/immunology , Mycoses/surgery , Nasal Polyps/surgery , Rhinitis/surgery , Rhinoplasty , Sinusitis/surgery , Adult , Aged , Antifungal Agents/therapeutic use , Chronic Disease , Cohort Studies , Female , Follow-Up Studies , Humans , Itraconazole/therapeutic use , Male , Middle Aged , Mycoses/complications , Mycoses/drug therapy , Nasal Polyps/complications , Nasal Polyps/drug therapy , Quality of Life , Rhinitis/complications , Rhinitis/drug therapy , Sinusitis/complications , Sinusitis/drug therapy , Surveys and Questionnaires , Treatment Outcome , Young Adult
6.
Genetics ; 201(3): 951-61, 2015 Nov.
Article in English | MEDLINE | ID: mdl-26400612

ABSTRACT

We show by whole genome sequence analysis that loss of RNase H2 activity increases loss of heterozygosity (LOH) in Saccharomyces cerevisiae diploid strains harboring the pol2-M644G allele encoding a mutant version of DNA polymerase ε that increases ribonucleotide incorporation. This led us to analyze the effects of loss of RNase H2 on LOH and on nonallelic homologous recombination (NAHR) in mutant diploid strains with deletions of genes encoding RNase H2 subunits (rnh201Δ, rnh202Δ, and rnh203Δ), topoisomerase 1 (TOP1Δ), and/or carrying mutant alleles of DNA polymerases ε, α, and δ. We observed an ∼7-fold elevation of the LOH rate in RNase H2 mutants encoding wild-type DNA polymerases. Strains carrying the pol2-M644G allele displayed a 7-fold elevation in the LOH rate, and synergistic 23-fold elevation in combination with rnh201Δ. In comparison, strains carrying the pol2-M644L mutation that decreases ribonucleotide incorporation displayed lower LOH rates. The LOH rate was not elevated in strains carrying the pol1-L868M or pol3-L612M alleles that result in increased incorporation of ribonucleotides during DNA synthesis by polymerases α and δ, respectively. A similar trend was observed in an NAHR assay, albeit with smaller phenotypic differentials. The ribonucleotide-mediated increases in the LOH and NAHR rates were strongly dependent on TOP1. These data add to recent reports on the asymmetric mutagenicity of ribonucleotides caused by topoisomerase 1 processing of ribonucleotides incorporated during DNA replication.


Subject(s)
Gene Rearrangement , Genes, Fungal , Ribonucleotides/metabolism , Saccharomyces cerevisiae/genetics , DNA Polymerase II/genetics , DNA Polymerase II/metabolism , DNA Replication , DNA Topoisomerases, Type I/genetics , DNA Topoisomerases, Type I/metabolism , DNA, Fungal/biosynthesis , Genomic Instability , Karyotype , Loss of Heterozygosity , Ribonucleases/genetics , Ribonucleases/metabolism , Saccharomyces cerevisiae/enzymology , Saccharomyces cerevisiae Proteins/genetics , Saccharomyces cerevisiae Proteins/metabolism , Sequence Analysis, DNA , Translocation, Genetic
7.
Neurol Clin Pract ; 5(3): 241-246, 2015 Jun.
Article in English | MEDLINE | ID: mdl-26124981

ABSTRACT

As health care laws and payment structures change in the near future, neurologists may pursue other practice settings in which to provide care as a way to diversify their practice. Here we describe the challenges and opportunities involved with working in correctional and state mental hospital systems compared to a typical private practice: logistical challenges, patient and provider safety, patient characteristics, and cultural differences. Neurologists may take these factors into consideration when choosing whether to add this health care setting to their current practice.

8.
Bioorg Med Chem Lett ; 25(21): 4941-4944, 2015 Nov 01.
Article in English | MEDLINE | ID: mdl-25987375

ABSTRACT

Facilitating activation, or delaying inactivation, of the native Kv7 channel reduces neuronal excitability, which may be beneficial in controlling spontaneous electrical activity during epileptic seizures. In an effort to identify a compound with such properties, the structure-activity relationship (SAR) and in vitro ADME for a series of heterocyclic Kv7.2-7.5 channel openers was explored. PF-05020182 (2) demonstrated suitable properties for further testing in vivo where it dose-dependently decreased the number of animals exhibiting full tonic extension convulsions in response to corneal stimulation in the maximal electroshock (MES) assay. In addition, PF-05020182 (2) significantly inhibited convulsions in the MES assay at doses tested, consistent with in vitro activity measure. The physiochemical properties, in vitro and in vivo activities of PF-05020182 (2) support further development as an adjunctive treatment of refractory epilepsy.


Subject(s)
Drug Discovery , Epilepsy/drug therapy , Ion Channel Gating/drug effects , KCNQ2 Potassium Channel/metabolism , Piperidines/pharmacology , Pyrimidines/pharmacology , Animals , Cell Line , Dose-Response Relationship, Drug , Electroshock , Humans , KCNQ2 Potassium Channel/agonists , Microsomes/drug effects , Molecular Structure , Piperidines/administration & dosage , Piperidines/chemistry , Pyrimidines/administration & dosage , Pyrimidines/chemistry , Rats , Structure-Activity Relationship
9.
Nucleic Acids Res ; 43(8): 4067-74, 2015 Apr 30.
Article in English | MEDLINE | ID: mdl-25824945

ABSTRACT

Mutation rates are used to calibrate molecular clocks and to link genetic variants with human disease. However, mutation rates are not uniform across each eukaryotic genome. Rates for insertion/deletion (indel) mutations have been found to vary widely when examined in vitro and at specific loci in vivo. Here, we report the genome-wide rates of formation and repair of indels made during replication of yeast nuclear DNA. Using over 6000 indels accumulated in four mismatch repair (MMR) defective strains, and statistical corrections for false negatives, we find that indel rates increase by 100 000-fold with increasing homonucleotide run length, representing the greatest effect on replication fidelity of any known genomic parameter. Nonetheless, long genomic homopolymer runs are overrepresented relative to random chance, implying positive selection. Proofreading defects in the replicative polymerases selectively increase indel rates in short repetitive tracts, likely reflecting the distance over which Pols δ and ϵ interact with duplex DNA upstream of the polymerase active site. In contrast, MMR defects hugely increase indel mutagenesis in long repetitive sequences. Because repetitive sequences are not uniformly distributed among genomic functional elements, the quantitatively different consequences on genome-wide repeat sequence instability conferred by defects in proofreading and MMR have important biological implications.


Subject(s)
DNA Mismatch Repair , Genomic Instability , INDEL Mutation , DNA-Directed DNA Polymerase/genetics , Genome, Fungal , Mutation , Mutation Rate , Repetitive Sequences, Nucleic Acid
10.
Nat Struct Mol Biol ; 22(4): 291-7, 2015 Apr.
Article in English | MEDLINE | ID: mdl-25751426

ABSTRACT

Ribonucleotides incorporated during DNA replication are removed by RNase H2-dependent ribonucleotide excision repair (RER). In RER-defective yeast, topoisomerase 1 (Top1) incises DNA at unrepaired ribonucleotides, initiating their removal, but this is accompanied by RNA-DNA-damage phenotypes. Here we show that these phenotypes are incurred by a high level of ribonucleotides incorporated by a leading strand-replicase variant, DNA polymerase (Pol) ɛ, but not by orthologous variants of the lagging-strand replicases, Pols α or δ. Moreover, loss of both RNases H1 and H2 is lethal in combination with increased ribonucleotide incorporation by Pol ɛ but not by Pols α or δ. Several explanations for this asymmetry are considered, including the idea that Top1 incision at ribonucleotides relieves torsional stress in the nascent leading strand but not in the nascent lagging strand, in which preexisting nicks prevent the accumulation of superhelical tension.


Subject(s)
DNA Topoisomerases, Type I/physiology , DNA/metabolism , Ribonucleotides/metabolism , Saccharomyces cerevisiae Proteins/physiology , DNA Polymerase II/metabolism , DNA Polymerase II/physiology , DNA Repair , DNA Replication , DNA Topoisomerases, Type I/metabolism , Saccharomyces cerevisiae/genetics , Saccharomyces cerevisiae Proteins/metabolism
11.
J Comput Aided Mol Des ; 29(9): 795-807, 2015 Sep.
Article in English | MEDLINE | ID: mdl-25697964

ABSTRACT

We demonstrate here a novel use of statistical tools to study intra- and inter-site assay variability of five early drug metabolism and pharmacokinetics in vitro assays over time. Firstly, a tool for process control is presented. It shows the overall assay variability but allows also the following of changes due to assay adjustments and can additionally highlight other, potentially unexpected variations. Secondly, we define the minimum discriminatory difference/ratio to support projects to understand how experimental values measured at different sites at a given time can be compared. Such discriminatory values are calculated for 3 month periods and followed over time for each assay. Again assay modifications, especially assay harmonization efforts, can be noted. Both the process control tool and the variability estimates are based on the results of control compounds tested every time an assay is run. Variability estimates for a limited set of project compounds were computed as well and found to be comparable. This analysis reinforces the need to consider assay variability in decision making, compound ranking and in silico modeling.


Subject(s)
Data Interpretation, Statistical , High-Throughput Screening Assays/methods , High-Throughput Screening Assays/statistics & numerical data , Pharmacokinetics , Animals , Biological Assay/statistics & numerical data , Blood Proteins/metabolism , Drug Evaluation, Preclinical/methods , Drug Evaluation, Preclinical/statistics & numerical data , Hepatocytes/drug effects , Hepatocytes/metabolism , Humans , Inactivation, Metabolic , Microsomes, Liver/drug effects , Microsomes, Liver/metabolism , Pharmaceutical Preparations/chemistry , Rats , Solubility
12.
Article in English | MEDLINE | ID: mdl-25286080

ABSTRACT

This study was aimed at determining whether, in the absence of a full genetic database for the Sheep Blowfly (Lucilia cuprina) glutathione transferases from this insect could be characterized by cross-database matching of MALDI TOF data with the database for other metazoan organisms. Glutathione transferases of L. cuprina were partially purified by the sequential use of affinity chromatography media; first on glutathione immobilized on epichlorohydrin-activated Sepharose 6B and subsequently on dinitrophenyl-glutathione immobilized on the same matrix. The Proteins obtained were separated by 2D SDS-PAGE and tentatively characterized by MALDI-TOF analysis of tryptic peptides. The mass fragments were matched against the NCBInr "Other metazoa" database. The GSTs matched to other insect species were identified as coming from the Sigma, Delta and Epsilon classes. The relative abundance of most of these GSTs appeared to vary little during development, or across bodily segments, an exception being one group, (Zone E) tentatively identified as Epsilon class, which was most prominent in eggs and absent from adults and which is therefore assumed to play a specific role in development.


Subject(s)
Databases, Protein , Diptera/genetics , Glutathione Transferase/chemistry , Proteome/chemistry , Animals , Diptera/growth & development , Glutathione Transferase/genetics , Glutathione Transferase/isolation & purification , Proteome/genetics , Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
13.
Genome Res ; 24(11): 1751-64, 2014 Nov.
Article in English | MEDLINE | ID: mdl-25217194

ABSTRACT

Mutational heterogeneity must be taken into account when reconstructing evolutionary histories, calibrating molecular clocks, and predicting links between genes and disease. Selective pressures and various DNA transactions have been invoked to explain the heterogeneous distribution of genetic variation between species, within populations, and in tissue-specific tumors. To examine relationships between such heterogeneity and variations in leading- and lagging-strand replication fidelity and mismatch repair, we accumulated 40,000 spontaneous mutations in eight diploid yeast strains in the absence of selective pressure. We found that replicase error rates vary by fork direction, coding state, nucleosome proximity, and sequence context. Further, error rates and DNA mismatch repair efficiency both vary by mismatch type, responsible polymerase, replication time, and replication origin proximity. Mutation patterns implicate replication infidelity as one driver of variation in somatic and germline evolution, suggest mechanisms of mutual modulation of genome stability and composition, and predict future observations in specific cancers.


Subject(s)
DNA Mismatch Repair , DNA Polymerase III/genetics , DNA Polymerase II/genetics , DNA Polymerase I/genetics , Genome, Fungal/genetics , Saccharomyces cerevisiae Proteins/genetics , Algorithms , DNA Polymerase I/metabolism , DNA Polymerase II/metabolism , DNA Polymerase III/metabolism , DNA Replication , Evolution, Molecular , Genetic Variation , Models, Genetic , Mutation Rate , Nucleosomes/genetics , Nucleosomes/metabolism , Saccharomyces cerevisiae/enzymology , Saccharomyces cerevisiae/genetics , Saccharomyces cerevisiae/metabolism , Saccharomyces cerevisiae Proteins/metabolism , Sequence Analysis, DNA
14.
Proc Natl Acad Sci U S A ; 110(27): E2470-9, 2013 Jul 02.
Article in English | MEDLINE | ID: mdl-23754438

ABSTRACT

Mammalian Exonuclease 1 (EXO1) is an evolutionarily conserved, multifunctional exonuclease involved in DNA damage repair, replication, immunoglobulin diversity, meiosis, and telomere maintenance. It has been assumed that EXO1 participates in these processes primarily through its exonuclease activity, but recent studies also suggest that EXO1 has a structural function in the assembly of higher-order protein complexes. To dissect the enzymatic and nonenzymatic roles of EXO1 in the different biological processes in vivo, we generated an EXO1-E109K knockin (Exo1(EK)) mouse expressing a stable exonuclease-deficient protein and, for comparison, a fully EXO1-deficient (Exo1(null)) mouse. In contrast to Exo1(null/null) mice, Exo1(EK/EK) mice retained mismatch repair activity and displayed normal class switch recombination and meiosis. However, both Exo1-mutant lines showed defects in DNA damage response including DNA double-strand break repair (DSBR) through DNA end resection, chromosomal stability, and tumor suppression, indicating that the enzymatic function is required for those processes. On a transformation-related protein 53 (Trp53)-null background, the DSBR defect caused by the E109K mutation altered the tumor spectrum but did not affect the overall survival as compared with p53-Exo1(null) mice, whose defects in both DSBR and mismatch repair also compromised survival. The separation of these functions demonstrates the differential requirement for the structural function and nuclease activity of mammalian EXO1 in distinct DNA repair processes and tumorigenesis in vivo.


Subject(s)
DNA Repair Enzymes/metabolism , Exodeoxyribonucleases/metabolism , Amino Acid Sequence , Amino Acid Substitution/genetics , Animals , DNA End-Joining Repair/genetics , DNA Mismatch Repair/genetics , DNA Repair Enzymes/deficiency , DNA Repair Enzymes/genetics , Exodeoxyribonucleases/deficiency , Exodeoxyribonucleases/genetics , Female , Male , Meiosis/genetics , Mice , Mice, 129 Strain , Mice, Inbred C57BL , Mice, Knockout , Mice, Mutant Strains , Molecular Sequence Data , Mutagenesis, Site-Directed , Mutant Proteins/chemistry , Mutant Proteins/genetics , Mutant Proteins/metabolism , Sequence Homology, Amino Acid
15.
Mol Cell ; 50(3): 437-43, 2013 May 09.
Article in English | MEDLINE | ID: mdl-23603118

ABSTRACT

To maintain genome stability, mismatch repair of nuclear DNA replication errors must be directed to the nascent strand, likely by DNA ends and PCNA. Here we show that the efficiency of mismatch repair in Saccharomyces cerevisiae is reduced by inactivating RNase H2, which nicks DNA containing ribonucleotides incorporated during replication. In strains encoding mutator polymerases, this reduction is preferential for repair of mismatches made by leading-strand DNA polymerase ε as compared to lagging-strand DNA polymerase δ. The results suggest that RNase-H2-dependent processing of ribonucleotides transiently present in DNA after replication may direct mismatch repair to the continuously replicated nascent leading strand.


Subject(s)
DNA Mismatch Repair , DNA Replication/genetics , Ribonucleotides/genetics , Ribonucleotides/metabolism , DNA Polymerase II/genetics , DNA Polymerase II/metabolism , DNA Polymerase III/genetics , DNA Polymerase III/metabolism , Genomic Instability , Ribonuclease H/genetics , Ribonuclease H/metabolism , Saccharomyces cerevisiae/enzymology , Saccharomyces cerevisiae/genetics , Saccharomyces cerevisiae/metabolism , Saccharomyces cerevisiae Proteins/genetics , Saccharomyces cerevisiae Proteins/metabolism
16.
PLoS Genet ; 8(10): e1003016, 2012.
Article in English | MEDLINE | ID: mdl-23071460

ABSTRACT

The two DNA strands of the nuclear genome are replicated asymmetrically using three DNA polymerases, α, δ, and ε. Current evidence suggests that DNA polymerase ε (Pol ε) is the primary leading strand replicase, whereas Pols α and δ primarily perform lagging strand replication. The fact that these polymerases differ in fidelity and error specificity is interesting in light of the fact that the stability of the nuclear genome depends in part on the ability of mismatch repair (MMR) to correct different mismatches generated in different contexts during replication. Here we provide the first comparison, to our knowledge, of the efficiency of MMR of leading and lagging strand replication errors. We first use the strand-biased ribonucleotide incorporation propensity of a Pol ε mutator variant to confirm that Pol ε is the primary leading strand replicase in Saccharomyces cerevisiae. We then use polymerase-specific error signatures to show that MMR efficiency in vivo strongly depends on the polymerase, the mismatch composition, and the location of the mismatch. An extreme case of variation by location is a T-T mismatch that is refractory to MMR. This mismatch is flanked by an AT-rich triplet repeat sequence that, when interrupted, restores MMR to > 95% efficiency. Thus this natural DNA sequence suppresses MMR, placing a nearby base pair at high risk of mutation due to leading strand replication infidelity. We find that, overall, MMR most efficiently corrects the most potentially deleterious errors (indels) and then the most common substitution mismatches. In combination with earlier studies, the results suggest that significant differences exist in the generation and repair of Pol α, δ, and ε replication errors, but in a generally complementary manner that results in high-fidelity replication of both DNA strands of the yeast nuclear genome.


Subject(s)
DNA Mismatch Repair , DNA Replication , Base Sequence , DNA Polymerase II/metabolism , Molecular Sequence Data , Mutagenesis , Mutation Rate , Saccharomyces cerevisiae/genetics , Saccharomyces cerevisiae/metabolism
17.
Drug Metab Dispos ; 40(3): 625-34, 2012 Mar.
Article in English | MEDLINE | ID: mdl-22190693

ABSTRACT

The pharmacokinetic properties of drugs may be altered by kinetic deuterium isotope effects. With specifically deuterated model substrates and drugs metabolized by aldehyde oxidase, we demonstrate how knowledge of the enzyme's reaction mechanism, species differences in the role played by other enzymes in a drug's metabolic clearance, and differences in systemic clearance mechanisms are critically important for the pharmacokinetic application of deuterium isotope effects. Ex vivo methods to project the in vivo outcome using deuterated carbazeran and zoniporide with hepatic systems demonstrate the importance of establishing the extent to which other metabolic enzymes contribute to the metabolic clearance mechanism. Differences in pharmacokinetic outcomes in guinea pig and rat, with the same metabolic clearance mechanism, show how species differences in the systemic clearance mechanism can affect the in vivo outcome. Overall, to gain from the application of deuteration as a strategy to alter drug pharmacokinetics, these studies demonstrate the importance of understanding the systemic clearance mechanism and knowing the identity of the metabolic enzymes involved, the extent to which they contribute to metabolic clearance, and the extent to which metabolism contributes to the systemic clearance.


Subject(s)
Aldehyde Oxidase/metabolism , Carbamates/pharmacokinetics , Deuterium/metabolism , Guanidines/pharmacokinetics , Pyrazoles/pharmacokinetics , Animals , Carbamates/metabolism , Cytosol/metabolism , Guanidines/metabolism , Guinea Pigs , Hepatocytes/metabolism , Humans , Kinetics , Liver/metabolism , Male , Pyrazoles/metabolism , Rats , Rats, Sprague-Dawley
18.
Article in English | MEDLINE | ID: mdl-22100830

ABSTRACT

The glutathione transferases (GSTs) are a large group of enzymes having both detoxication roles and specialist metabolic functions. The present work represents an initial approach to identifying some of these roles by examining the variation of specific members of the family under differing conditions. The GSTs from Lucilia cuprina have been partially purified, members of two families being isolated, by the use of glutathione immobilised on epichlorhydrin-activated Sepharose 6B. The GSTs were separated by 2D SDS-PAGE and characterised by MALDI-TOF analysis of tryptic peptides. The mass fragments were then matched against the corresponding Drosophila melanogaster and Musca domestica sequences. GSTs were identified as coming from only the Sigma and Delta classes. The multiple Delta zones appear all to be derived from the Lucilia GSTD1 isoform. The distribution of these GST proteins has been studied during different developmental stages of the insect. Delta isoforms were present in all developmental stages of L. cuprina. The Sigma GST was not detectable in the egg, was just detectable in the larval and pupal stages and was the major GST isolated in the adult. Sigma and Delta isoforms were both found in all body segments of the insect. Both isoforms appear to undergo extensive post-translational modification. Activities of the two types of protein with model substrates have been determined.


Subject(s)
Diptera/enzymology , Diptera/growth & development , Gene Expression Regulation, Developmental , Glutathione Transferase/genetics , Amino Acid Sequence , Animals , Diptera/chemistry , Diptera/genetics , Drosophila melanogaster/chemistry , Drosophila melanogaster/enzymology , Glutathione Transferase/analysis , Glutathione Transferase/chemistry , Houseflies/chemistry , Houseflies/enzymology , Molecular Sequence Data , Protein Isoforms/analysis , Protein Isoforms/chemistry , Protein Isoforms/genetics , Sequence Alignment
19.
Science ; 332(6037): 1561-4, 2011 Jun 24.
Article in English | MEDLINE | ID: mdl-21700875

ABSTRACT

The ribonuclease (RNase) H class of enzymes degrades the RNA component of RNA:DNA hybrids and is important in nucleic acid metabolism. RNase H2 is specialized to remove single ribonucleotides [ribonucleoside monophosphates (rNMPs)] from duplex DNA, and its absence in budding yeast has been associated with the accumulation of deletions within short tandem repeats. Here, we demonstrate that rNMP-associated deletion formation requires the activity of Top1, a topoisomerase that relaxes supercoils by reversibly nicking duplex DNA. The reported studies extend the role of Top1 to include the processing of rNMPs in genomic DNA into irreversible single-strand breaks, an activity that can have distinct mutagenic consequences and may be relevant to human disease.


Subject(s)
DNA Topoisomerases, Type I/metabolism , DNA, Fungal/metabolism , Mutagenesis , Ribonucleotides/metabolism , Saccharomyces cerevisiae/genetics , Saccharomyces cerevisiae/metabolism , Sequence Deletion , Amino Acid Transport Systems, Basic/genetics , Base Sequence , Camptothecin/pharmacology , Canavanine/pharmacology , DNA Breaks , DNA, Fungal/chemistry , DNA, Single-Stranded/metabolism , Microsatellite Repeats , Molecular Sequence Data , Nucleic Acid Conformation , Ribonuclease H/genetics , Ribonuclease H/metabolism , Saccharomyces cerevisiae/enzymology , Saccharomyces cerevisiae Proteins/genetics , Transcription, Genetic
20.
Nature ; 474(7350): 230-4, 2011 Jun 08.
Article in English | MEDLINE | ID: mdl-21654808

ABSTRACT

Cyclin D1 is a component of the core cell cycle machinery. Abnormally high levels of cyclin D1 are detected in many human cancer types. To elucidate the molecular functions of cyclin D1 in human cancers, we performed a proteomic screen for cyclin D1 protein partners in several types of human tumours. Analyses of cyclin D1 interactors revealed a network of DNA repair proteins, including RAD51, a recombinase that drives the homologous recombination process. We found that cyclin D1 directly binds RAD51, and that cyclin D1-RAD51 interaction is induced by radiation. Like RAD51, cyclin D1 is recruited to DNA damage sites in a BRCA2-dependent fashion. Reduction of cyclin D1 levels in human cancer cells impaired recruitment of RAD51 to damaged DNA, impeded the homologous recombination-mediated DNA repair, and increased sensitivity of cells to radiation in vitro and in vivo. This effect was seen in cancer cells lacking the retinoblastoma protein, which do not require D-cyclins for proliferation. These findings reveal an unexpected function of a core cell cycle protein in DNA repair and suggest that targeting cyclin D1 may be beneficial also in retinoblastoma-negative cancers which are currently thought to be unaffected by cyclin D1 inhibition.


Subject(s)
Cyclin D1/metabolism , DNA Repair , Neoplasms/metabolism , Protein Interaction Mapping , Rad51 Recombinase/metabolism , Animals , Cell Line, Tumor , Comet Assay , Cyclin D1/deficiency , DNA Damage/radiation effects , DNA Repair/radiation effects , HeLa Cells , Humans , Mice , Neoplasms/genetics , Neoplasms/pathology , Protein Binding/radiation effects , Radiation, Ionizing , Recombination, Genetic/genetics , Retinoblastoma Protein/deficiency
SELECTION OF CITATIONS
SEARCH DETAIL
...